Marco Platania

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

Emilio Bajetta, Laura Catena, Giuseppe Procopio et al. · Cancer Chemotherapy and Pharmacology · 2006 · 241 citations

Oncology, Medicine, Are Capecitabine +7

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

Barbro Eriksson, Bruno Annibale, Emilio Bajetta et al. · Neuroendocrinology · 2009 · 94 citations · Full text

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study

Roberto Buzzoni, Sara Pusceddu, Emilio Bajetta et al. · Annals of Oncology · 2014 · 68 citations · Full text

Medicine, Cancer Management, Biliary Cancer +6

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

M. Pérol, Nick Pavlakis, E. Levchenko et al. · Lung Cancer · 2019 · 55 citations · Full text

Patient-reported Outcomes, Medicine, Cancer Management +6